Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pyxis Oncology Inc (PYXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PYXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.2
1 Year Target Price $6.2
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.88% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.34M USD | Price to earnings Ratio - | 1Y Target Price 6.2 |
Price to earnings Ratio - | 1Y Target Price 6.2 | ||
Volume (30-day avg) 7 | Beta 1.13 | 52 Weeks Range 0.83 - 5.39 | Updated Date 08/29/2025 |
52 Weeks Range 0.83 - 5.39 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.34 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -676.1% |
Management Effectiveness
Return on Assets (TTM) -31.25% | Return on Equity (TTM) -74.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13002119 | Price to Sales(TTM) 29.91 |
Enterprise Value 13002119 | Price to Sales(TTM) 29.91 | ||
Enterprise Value to Revenue 4.61 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 62018100 | Shares Floating 41180042 |
Shares Outstanding 62018100 | Shares Floating 41180042 | ||
Percent Insiders 23.39 | Percent Institutions 33.74 |
Upturn AI SWOT
Pyxis Oncology Inc
Company Overview
History and Background
Pyxis Oncology Inc. is a clinical stage oncology company founded in 2019, initially incubated by Longwood Fund. It focuses on developing novel therapies to address difficult-to-treat cancers. The company has grown through internal development and strategic partnerships.
Core Business Areas
- Antibody-Drug Conjugates (ADCs): Development of ADCs targeting specific cancer cells to deliver cytotoxic payloads.
- Immunotherapies: Development of therapies to enhance the body's immune system to fight cancer.
- Small Molecule Inhibitors: Discovering and developing small molecules designed to inhibit key cancer-promoting pathways.
Leadership and Structure
Lara S. Sullivan, M.D., serves as the President and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- PYX-106: An anti-Siglec-15 antibody designed to block the activity of Siglec-15, an immunosuppressive molecule. Phase 1 clinical trials are underway. Competitors include companies developing similar immune checkpoint inhibitors.
- PYX-201: An Antibody-Drug Conjugate (ADC) targeting ENPP1. Phase 1 clinical trials are underway. Competitors include companies with ADC development programs.
Market Dynamics
Industry Overview
The oncology therapeutics market is characterized by high growth, intense competition, and significant unmet medical needs. Key trends include personalized medicine, immunotherapy, and targeted therapies.
Positioning
Pyxis Oncology is positioned as a clinical-stage biotechnology company focused on developing innovative cancer therapies. Its competitive advantage lies in its novel targets and therapeutic modalities.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of USD. Pyxis Oncology is targeting specific subsets of cancer patients, addressing a portion of the total market. TAM is dependent on the approval of PYX-106 and PYX-201.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets (Siglec-15, ENPP1)
- Experienced management team
- Focus on difficult-to-treat cancers
- Partnerships and collaborations
Weaknesses
- Early-stage clinical development (high risk)
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial outcomes
- No currently marketed products
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new targets and technologies
- Potential for accelerated regulatory approval pathways
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting funding for biotech companies
Competitors and Market Share
Key Competitors
- MRTX
- TSRO
- IMVT
Competitive Landscape
Pyxis Oncology faces competition from established pharmaceutical companies and other biotechnology companies developing cancer therapies. Their advantage lies in their unique targets and therapeutic modalities.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily through pipeline development and clinical trial progress.
Future Projections: Future growth depends on clinical trial success and regulatory approvals. Analyst estimates are not provided because they are very variable for a company in this sector.
Recent Initiatives: Recent strategic initiatives include advancing PYX-106 and PYX-201 through clinical trials, exploring new targets and technologies, and seeking partnerships.
Summary
Pyxis Oncology is a clinical-stage company with novel therapeutic targets and significant pipeline risk. Its strengths lie in innovative approaches to cancer treatment and a focus on difficult-to-treat cancers. The company's success depends on clinical trial outcomes, partnerships, and effectively managing its limited resources, with the high risks associated with oncology therapeutics development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- ClinicalTrials.gov
- Yahoo Finance
- Google Finance
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary depending on the source. All investment decisions should be made with the advice of a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | CEO, President, Chief Medical Officer & Director Dr. Lara S. Sullivan M.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.pyxisoncology.com |
Full time employees 44 | Website https://www.pyxisoncology.com | ||
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.